 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «123 |
- | islatravir (MK-8591) / Merck (MSD)
Trial primary completion date, Combination therapy: DRIVE2Simplify: Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011) (clinicaltrials.gov) - Apr 16, 2019
P2b, N=120, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Apr 2019 --> Oct 2020
- ||| islatravir (MK-8591) / Merck (MSD)
Enrollment closed, Combination therapy: DRIVE2Simplify: Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011) (clinicaltrials.gov) - Apr 26, 2018
P2b, N=120, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Apr 2019 --> Oct 2020 Recruiting --> Active, not recruiting
- |||| islatravir (MK-8591) / Merck (MSD)
Enrollment open, Combination therapy: DRIVE2Simplify: Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011) (clinicaltrials.gov) - Dec 12, 2017
P2b, N=120, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||| islatravir (MK-8591) / Merck (MSD)
New P2b trial, Combination therapy: DRIVE2Simplify: Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011) (clinicaltrials.gov) - Sep 4, 2017
P2b, N=120, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.